ARS Pharmaceuticals Files 8-K

Ticker: SPRY · Form: 8-K · Filed: Mar 7, 2024 · CIK: 1671858

Ars Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyArs Pharmaceuticals, Inc. (SPRY)
Form Type8-K
Filed DateMar 7, 2024
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.0001, $228 million
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, regulation-fd

TL;DR

ARS Pharma filed an 8-K, expect financial and operational updates soon.

AI Summary

ARS Pharmaceuticals, Inc. filed an 8-K on March 7, 2024, to report on its results of operations and financial condition, as well as to provide Regulation FD disclosures and file financial statements and exhibits. The filing does not contain specific financial figures or operational updates beyond the general reporting categories.

Why It Matters

This 8-K filing indicates ARS Pharmaceuticals is providing updates on its financial condition and operations, which could contain material information for investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting financial and operational information, not indicating any immediate adverse events.

Key Players & Entities

  • ARS Pharmaceuticals, Inc. (company) — Registrant
  • Delaware (jurisdiction) — State of incorporation
  • Silverback Therapeutics, Inc. (company) — Former company name

FAQ

What specific financial results are being reported in this 8-K?

The filing indicates 'Results of Operations and Financial Condition' are being reported, but specific dollar amounts or detailed financial statements are not provided in the initial summary of the 8-K.

What is the purpose of the Regulation FD Disclosure mentioned in the filing?

Regulation FD (Fair Disclosure) disclosures are made to prevent selective disclosure of material nonpublic information, ensuring all investors receive such information simultaneously.

When was ARS Pharmaceuticals, Inc. formerly known as Silverback Therapeutics, Inc.?

The date of the name change from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc. was April 12, 2016.

What is the principal executive office address for ARS Pharmaceuticals, Inc.?

The principal executive offices are located at 11682 El Camino Real, Suite 120, San Diego, California, 92130.

What is the SIC code for ARS Pharmaceuticals, Inc.?

The Standard Industrial Classification (SIC) code for ARS Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 695 words · 3 min read · ~2 pages · Grade level 10.8 · Accepted 2024-03-07 12:56:52

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SPRY The Nasdaq
  • $228 million — December 31, 2023, it had approximately $228 million in cash and short-term investments. T

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Company Presentation, dated March 7, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 7, 2024 ARS Pharmaceuticals, Inc. By: /s/ Richard Lowenthal, M.S., MBA Name: Richard Lowenthal, M.S., MBA Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.